Skip to content
    CNC
    Earnings call· Jun 2026(Q2 FY26)

    CENTENE Q2 FY26 earnings call CNC

    Jul 28, 2026 Source

    Executive summary

    Centene Q2 FY26 — Strong Performance Drives Significant EPS Guidance Increase

    Centene delivered strong Q2 FY26 results, significantly raising its full-year adjusted EPS guidance driven by outperformance in Marketplace and Medicare PDP. While Medicaid membership saw a larger-than-expected decline, favorable rate adjustments and disciplined execution supported segment performance. The company is actively leveraging AI and optimizing its enterprise to drive efficiencies and long-term margin restoration amidst a dynamic healthcare landscape.

    Highlights

    5
    • Q2 adjusted diluted EPS of $2.51 exceeded expectations.

    • Full-year 2026 adjusted diluted EPS guidance raised to greater than $4.80, up from $3.40.

    • Marketplace pretax margin guidance improved to 4.5%-5%, from 3%.

    • Medicaid 7/1 rates came in better than expected, improving full-year composite rate forecast to 5% from 4.5%.

    • Medicare segment delivered outperformance, with PDP pretax margin now expected to be greater than 3%.

    Concerns

    5
    • Medicaid membership step-down was slightly larger than anticipated, ending Q2 with 12.1 million members.

    • Full-year Medicaid membership expected to be down 8%-9% compared to 12/31/25, versus prior view of down 6%.

    • Medicare Advantage faces headwinds from artificial cut point increases and program methodology changes in STARS.

    • Approximately $0.50 of Q2 EPS linked to 2025 settlements is not expected to recur in 2027.

    • Expect a little above breakeven in Q3 and a loss in Q4 due to seasonal sloping of Medicare Part D and Commercial products.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2026 Adjusted Diluted EPS
    greater than $4.80
    high materiality
    High
    Full-year 2026 Medicaid Composite Rate Forecast
    roughly 5%
    medium materiality
    High
    Full-year 2026 PDP Pretax Margin
    greater than 3%
    medium materiality
    High
    Full-year 2026 Medicare Advantage Breakeven
    breakeven or better
    medium materiality
    High
    Full-year 2026 Marketplace Pretax Margin
    between 4.5% and 5%
    high materiality
    High
    Full-year 2026 Medicaid Membership Decline
    down 8% to 9%
    medium materiality
    Medium
    Full-year 2026 Enterprise Adjusted SG&A Rate
    better by 10 basis points
    medium materiality
    High
    Full-year 2026 Workforce and Enterprise Optimization SG&A Costs
    estimated $480 million midpoint
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Medicaid
    Medicaid results were on track with prior forecast. HBR of 93.9% in Q2, with full-year HBR expected around 93.5%. 7/1 rate cohort came in strong, improving full-year rate impact to 5%. Expect full-year membership to be down 8-9% compared to 12/31/25, higher than prior view of 6%.
    Membership: 12.1 million membersFull-year HBR expectation: around 93.5%Full-year 2026 rate impact: approximately 5%Fundamental trend: mid-4s
    93.9% HBR
    Medicare
    Medicare segment results were strong, with an HBR of 89.5%, including a $160 million 2025 settlement. PDP is having a strong year, with pretax margin expected to be greater than 3%. Medicare Advantage continued to perform well, getting closer to breakeven for full-year 2026. D-SNP members continue to perform favorably.
    PDP full-year pretax margin: greater than 3%Medicare Advantage segment revenue contribution: a little over 40%Medicare Advantage full-year 2026 performance: closer to breakevenD-SNP members: approximately 40% of Medicare Advantage portfolio
    89.5% HBR
    Commercial (Marketplace)
    Commercial segment, led by Marketplace, had a very strong quarter with an HBR of 79.2%, compared to 90.6% prior year. Driven by strong end to 2025, confirmation of 2026 market acuity, and tapering medical trend. Marketplace pretax margin now expected to be 4.5% to 5%. Membership was stable compared to Q1 at 3.5 million members.
    Marketplace pretax margin: 4.5% to 5%Marketplace membership: 3.5 million members
    79.2% HBR

    Operational metrics

    22
    Adjusted Diluted EPS from 2025 Settlements
    $0.50not expected to recur in 2027
    Q2 FY26

    Approximately $0.50 of earnings in Q2 were linked to settlements of 2025 items.

    Marketplace 2025 Risk Adjustment Net Favorability
    $180 millionrelative to prior guidance
    Q2 FY26

    Favorable development on final 2025 CMS risk adjustment reconciliation, contributing to Q2 results. This is part of the $0.50 EPS from 2025 settlements.

    Medicare Segment 2025 Settlements
    $160 million
    Q2 FY26

    Part of the $0.50 EPS from 2025 settlements.

    Consolidated HBR
    89.6%down from 93% in Q2 2025
    Q2 FY26

    Reflects strong performance across segments.

    Adjusted SG&A Expense Ratio
    6.9%compared to 7.1% last year
    Q2 FY26

    Reflecting continued discipline and scale as well as product mix.

    Cash Available for General Corporate Use
    $715 million
    Q2 FY26

    Balance at the end of the quarter.

    Senior Notes Repurchased
    $260 million
    Q2 FY26

    Repurchased during the second quarter in an effort to delever.

    Debt-to-Cap Ratio
    41.6%down from 46.5% at year-end
    Q2 FY26

    Reflects continued deleveraging efforts.

    Medical Claims Liability
    $20.3 billion
    Q2 FY26

    Total medical claims liability.

    Days in Claims Payable (DCP)
    47 daysdecrease of 1 day as compared to Q1 2026
    Q2 FY26

    Driven by timing of state-directed payments.

    Medicaid Pass-Through Payments Expected in Q3
    over $3 billion
    Q3 FY26

    Expected to be paid out in Q3, currently sitting on the balance sheet.

    Total Premium and Service Revenue
    $44.4 billion
    Q2 FY26

    Reported for the second quarter 2026.

    Year-to-Date Adjusted EPS
    $5.88
    YTD FY26

    Reported year-to-date adjusted EPS.

    Marketplace 2025 Risk Adjustment Reconciliation (Total)
    $481 million
    FY25

    Total favorable development on 2025 CMS risk adjustment reconciliation. After accounting for $250M of expected annual margin release and $50M of other deducts, $180M was better than prior guidance.

    Marketplace Pretax Margin Midpoint
    4.75%up from 3%
    FY26

    Midpoint of the updated full-year Marketplace pretax margin guidance of 4.5% to 5%.

    ICHRA Membership Growth
    2.5x
    YoY

    ICHRA business grew 2.5 times since last year, reaching approximately 50,000 members.

    Medicaid Health Plans NCQA Quality Ratings Target
    75%
    current cycle

    Target for Medicaid health plans to achieve NCQA quality ratings at or better than 3.5 stars.

    PDP Pharmacy Spend Leverage
    greater than $60 billion
    annualized

    Leveraging pharmacy spend through partnership with ESI to deliver industry-leading cost structure.

    PDP Premium Revenue
    roughly $25 billion
    annualized

    PDP business hits post IRA stability, delivering consistent margin on this premium revenue.

    Legal Bills Savings from AI Agent
    1.5 points
    monthly

    AI agent reviews invoices from outside counsel firms, saving 1.5 points in legal bills every month.

    Medicaid Expansion Population as % of Portfolio
    18%down from 20% at start of year
    end of FY26

    Expected percentage of Medicaid portfolio by year-end, reflecting attrition.

    ICHRA Membership
    50,000 members2.5x growth since last year
    current

    Current membership in the ICHRA business.

    Industry KPIs

    7
    MetricValueDetails
    Utilization trendselevated
    Stars rate environmentyear-over-year improvement
    Medical loss care ratio89.6%%
    Pharmacy scripts specialtygreater than $60 billionUSD
    Membership covered lives by line12.1 millionmembers
    Adjusted EPS EBITDA leverage guidancegreater than $4.80USD/share
    Medical cost trend vs pricing assumptionmid-4s%

    Risks & headwinds

    5
    Increased Medicaid Membership AttritionH2 FY26

    Full-year Medicaid membership expected to be down 8%-9% compared to 12/31/25, versus prior view of down 6%.

    Mitigation: Holding back 50 basis points of rate favorability to account for higher membership attrition and associated acuity impact; engaging with state partners on OB3 implementation and rate adjustments.

    Medicare Advantage STARS Program HeadwindsOngoing

    Artificial cut point increases and overall STARS program methodology changes.

    Mitigation: Portfolio optimization, strong operational execution, SG&A management, and strategic duals growth to accelerate margin improvement and achieve breakeven or better results in 2027.

    Seasonal Earnings TrajectoryH2 FY26

    Expect a little above breakeven in Q3 and a loss in Q4.

    Mitigation: Consistent with prior year and commentary, reflecting seasonal sloping of Medicare Part D and Commercial products.

    Non-recurring 2025 SettlementsFY27

    Approximately $0.50 of Q2 EPS linked to 2025 settlements not expected to recur in 2027.

    Mitigation: Management has clearly identified this as a reconciling item for 2027 guidance, allowing for appropriate forward planning.

    Medicaid Acuity Shift from OB3FY27-FY29

    Potential for acuity impact as the Medicaid expansion population moves due to OB3 implementation.

    Mitigation: Engaging with state actuaries for OB3-related rate adjustments, leveraging data for ex parte eligibility, and activating nationwide playbook for member support and community engagement.

    What to watch in Q3 FY26

    5

    Medicaid Membership Attrition

    Next quarter
    CurrentDown 8-9% expected for FY26
    TargetStabilization or moderation of decline

    Why it matters

    Continued high attrition could impact acuity and margin, requiring further rate adjustments or operational offsets.

    As we look ahead to Q3, our 7/1 rate cohort, which represents about 20% of our membership, came in strong. This 7/1 cohort provides a nice sequential benefit from Q2 to Q3 to make progress toward matching rate and cost. Overall, we now expect the full year 2026 rate impact to be approximately 5%, up from 4.5%, with no change in our view of fundamental trend of mid-4s for the year. As some of you have written about, we did continue to see attrition in our Medicaid membership, ending Q2 with 12.1 million members, and we expect some states to continue to trim Medicaid roles leading up to any OB3 implementation in 2027. So for now, we are holding the incremental 50 basis point benefit of the rate improvement to account for a little higher membership attrition in the back half of the year, including the associated acuity impact.

    Q&A highlights

    5

    What's driving the higher acuity population stepping down in Medicaid, and is this a pull-forward of OB3 impact? How does this bridge to next year's acuity?

    The slight incremental attrition in Q2 was mainly in the expansion population, driven by state-specific changes and increased enrollment/eligibility activity. This led to a slight uptick in acuity, which the company absorbed. Management is holding back 50 basis points of rate favorability to account for potential acuity impacts from further attrition. It's possible this is a pull-forward of OB3 activity, with states tightening criteria. Centene is deeply involved in planning with states to minimize disruption and ensure appropriate rate adjustments.

    I think it's possible that that will end up being some degree of pull forward. Again, we're accounting for that as we think about guidance for the back half of the year.

    asked by John Stansel · answered by Sarah London

    2 min read6 chapters

    Detailed Narrative

    01

    Medicaid Performance and OB3 Preparation

    Medicaid results were in line with expectations, despite a slightly larger step-down in membership to 12.1 million members, driven by state-specific program changes and increased enrollment/eligibility activity. The company is heavily engaged with state partners for OB3 implementation, investing in real-time data exchange, member outreach, and community engagement programs. Management expects full-year Medicaid membership to decline 8-9% and is holding back 50 basis points of rate favorability to account for potential acuity impacts from attrition.

    02

    Medicare Segment Strength and Strategy

    The Medicare segment delivered outperformance, with continued strength in both PDP and Medicare Advantage. PDP benefited from prior-period true-up📎s and fundamental favorability, leading to an improved pretax margin outlook of greater than 3%. Medicare Advantage is performing well, with a focus on simplifying its footprint and concentrating benefits on the duals population, aiming for breakeven or better results in 2027 despite STARS program headwinds.

    03

    Marketplace Margin Recovery and Wakely Report Impact

    Marketplace delivered excellent Q2 results, achieving meaningful margin recovery. A thorough analysis of the June Wakely report confirmed the hypothesis about the relative acuity of Centene's population, allowing for a revised full-year pretax margin expectation of 4.5%-5%. Favorable development on the 2025 CMS risk adjustment reconciliation contributed $180 million in the quarter. The business expects membership to decline with a return to regular seasonality and accounts for CMS program integrity efforts.

    04

    Enterprise Optimization and AI Strategy

    Centene is undergoing an enterprise optimization to drive efficiencies, including further digitization and ubiquitous use of technology and AI. The AI strategy focuses on foundational capabilities like trusted data products and dynamic context management, prioritizing investments with clear, tangible ROI. This disciplined approach aims to unlock AI's full potential while maintaining compliance and supporting the goal of industry-leading outcomes with an industry-leading cost structure.

    05

    Medical Cost Drivers and Management

    Core medical cost drivers remained consistent, with behavioral health, home health, and high-cost drugs among top contributors. A slight uptick in acuity from the expansion population was absorbed due to strong execution. The company noted a year-over-year moderation in behavioral health, particularly ABA, due to focused efforts. Progress was also made in payment integrity, particularly in areas susceptible to AI up-coding like sepsis, by implementing algorithms and clinical conversations to ensure correct payment for care delivered.

    06

    ICHRA Business Growth and Outlook

    Centene's ICHRA business currently serves approximately 50,000 members, representing 2.5x growth since last year. Management sees continued interest in ICHRA as an alternative due to rising employer costs and deteriorating small group options in many geographies. The company remains bullish on ICHRA as a future option, offering choice, portability, and affordability, despite it being a smaller portion of the overall portfolio.

    AI-generated summary of the company’s earnings call. Not investment advice.